Profile data is unavailable for this security.
About the company
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
- Revenue in CHF (TTM)6.72bn
- Net income in CHF654.00m
- Incorporated2002
- Employees18.00k
- LocationLonza Group AGMuenchensteinerstrasse 38BASEL 4002SwitzerlandCHE
- Phone+41 613168111
- Fax+41 613169111
- Websitehttps://www.lonza.com/
More ▼
Mergers & acquisitions
| Acquired company | LONN:SWX since announced | Transaction value |
|---|---|---|
| Genentech Inc-Biologics Manufacturing Facility,Vacaville,California | 6.59% | 1.20bn |
| Synaffix BV | -9.73% | 171.01m |
Data delayed at least 15 minutes, as of Apr 30 2024 10:46 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Swedish Orphan Biovitrum AB (publ) | 1.93bn | 178.53m | 8.37bn | 1.75k | 45.79 | 2.68 | 18.08 | 4.34 | 6.19 | 6.19 | 69.32 | 105.59 | 0.3603 | 1.50 | 4.72 | 13,058,130.00 | 3.33 | 5.93 | 4.43 | 7.60 | 76.60 | 77.42 | 9.25 | 16.61 | 0.4994 | 3.56 | 0.3487 | 0.00 | 17.74 | 19.34 | -8.68 | -0.0729 | 53.61 | -- |
| Qiagen NV | 1.79bn | 310.81m | 8.53bn | 5.97k | 27.43 | 2.43 | 17.13 | 4.76 | 1.42 | 1.42 | 8.20 | 16.05 | 0.3169 | 1.93 | 5.38 | 307,269.60 | 5.50 | 5.41 | 6.60 | 6.53 | 62.77 | 64.65 | 17.37 | 16.35 | 1.62 | -- | 0.2839 | -- | -8.23 | 5.53 | -19.35 | 12.38 | 1.55 | -- |
| Ipsen SA | 3.23bn | 602.38m | 9.20bn | 5.33k | 15.22 | 2.43 | 9.85 | 2.85 | 7.39 | 7.72 | 39.66 | 46.25 | 0.554 | 1.99 | 5.23 | 620,920.20 | 10.48 | 9.71 | 13.93 | 13.33 | 82.72 | 82.76 | 18.91 | 16.02 | 0.989 | 30.43 | 0.089 | 19.23 | 4.75 | 7.08 | 4.03 | 9.75 | -8.65 | 3.71 |
| Recordati Industria Chmc Frmctc SpA | 2.03bn | 379.93m | 10.09bn | 4.46k | 26.25 | 6.04 | 19.22 | 4.96 | 1.88 | 1.88 | 10.08 | 8.19 | 0.5075 | 1.59 | 5.16 | 467,414.40 | 9.48 | 11.67 | 12.40 | 15.02 | 68.32 | 70.43 | 18.69 | 21.45 | 0.795 | 8.34 | 0.5175 | 42.46 | 12.36 | 9.02 | 24.61 | 4.50 | 81.68 | 5.46 |
| Eurofins Scientific SE | 6.36bn | 504.18m | 11.06bn | 61.80k | 22.49 | 2.22 | 10.00 | 1.74 | 2.61 | 1.30 | 32.92 | 26.44 | 0.6213 | 36.20 | 4.79 | 105,417.60 | 5.41 | 7.49 | 6.70 | 9.36 | 20.93 | 23.78 | 8.71 | 11.23 | 1.38 | 8.43 | 0.4332 | 19.28 | -2.94 | 11.49 | -21.53 | 10.91 | 8.58 | 11.66 |
| BioMerieux SA | 3.59bn | 349.07m | 11.82bn | 14.65k | 33.99 | 3.22 | 19.65 | 3.30 | 3.01 | 3.01 | 30.93 | 31.76 | 0.7036 | 1.97 | 5.00 | 250,815.60 | 6.18 | 9.30 | 7.88 | 12.31 | 55.99 | 56.51 | 8.78 | 12.38 | 1.19 | -- | 0.1215 | 17.76 | 2.39 | 8.70 | -20.95 | 6.87 | 8.36 | 19.42 |
| Sandoz Group AG | -100.00bn | -100.00bn | 13.16bn | 23.85k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.23 | -- | -90.92 | -- | -- | -- |
| Genmab A/S | 2.16bn | 569.59m | 17.05bn | 2.20k | 29.83 | 4.07 | -- | 7.91 | 66.05 | 66.05 | 249.95 | 483.85 | 0.5037 | -- | 3.09 | 7,474,592.00 | 13.31 | 17.43 | 14.25 | 18.59 | 55.82 | -- | 26.42 | 35.87 | 13.32 | -- | 0.0238 | -- | 13.57 | 40.35 | -20.18 | 24.21 | -4.66 | -- |
| argenx SE | 1.12bn | -268.69m | 20.17bn | 1.15k | -- | 5.38 | -- | 18.06 | -4.80 | -4.80 | 20.07 | 64.58 | 0.3195 | 0.4373 | 3.72 | 996,563.40 | -7.69 | -17.65 | -8.49 | -19.79 | 90.39 | -- | -24.06 | -97.72 | 9.01 | -- | 0.0049 | -- | 198.56 | 117.25 | 58.42 | -- | 122.32 | -- |
| UCB SA | 5.13bn | 334.82m | 23.46bn | 9.08k | 70.18 | 2.61 | 23.24 | 4.58 | 1.76 | 1.76 | 26.91 | 47.30 | 0.3345 | 1.76 | 4.63 | 578,223.10 | 2.18 | 5.03 | 2.67 | 6.28 | 67.50 | 72.21 | 6.53 | 12.66 | 0.9224 | 3.14 | 0.2529 | 36.44 | -4.80 | 2.54 | -18.33 | -15.41 | -1.51 | 2.36 |
| Bayer AG | 46.50bn | -2.87bn | 26.46bn | 99.72k | -- | 0.8232 | 3.63 | 0.569 | -2.99 | -2.99 | 48.49 | 33.52 | 0.3951 | 1.43 | 4.85 | 477,693.20 | -2.44 | -1.79 | -3.34 | -2.38 | 58.54 | 59.02 | -6.18 | -4.80 | 0.8015 | 3.40 | 0.5764 | -- | -6.11 | 5.33 | -170.87 | -- | 1.19 | -47.66 |
| HALEON PLC | 12.93bn | 1.20bn | 34.61bn | 24.00k | 29.36 | 1.84 | 49.28 | 2.68 | 0.1128 | 0.1128 | 1.22 | 1.80 | 0.3282 | 3.15 | 5.76 | 470,916.70 | 3.23 | -- | 3.73 | -- | 61.59 | -- | 9.83 | -- | 0.7349 | 7.37 | 0.3611 | -- | 4.09 | -- | -1.04 | -- | -- | -- |
| Lonza Group AG | 6.72bn | 654.00m | 38.90bn | 18.00k | 58.92 | 3.99 | 31.65 | 5.79 | 8.87 | 8.87 | 91.16 | 131.07 | 0.3928 | 2.80 | 5.84 | 373,166.70 | 3.83 | 5.07 | 4.64 | 6.21 | 29.00 | 39.15 | 9.75 | 14.52 | 1.20 | 11.86 | 0.2275 | 30.57 | 7.94 | 3.92 | -46.17 | -0.0306 | 23.95 | 7.78 |
Data as of Apr 30 2024. Currency figures normalised to Lonza Group AG's reporting currency: Swiss Franc CHF
17.84%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 05 Apr 2024 | 2.56m | 3.44% |
| Norges Bank Investment Managementas of 12 Apr 2024 | 2.23m | 2.99% |
| UBS Asset Management Switzerland AGas of 02 Apr 2024 | 1.86m | 2.49% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 1.19m | 1.60% |
| Z�rcher Kantonalbank (Investment Management)as of 29 Feb 2024 | 1.06m | 1.42% |
| BlackRock Investment Management (UK) Ltd.as of 31 Mar 2024 | 947.03k | 1.27% |
| Invesco Advisers, Inc.as of 31 Mar 2024 | 889.78k | 1.20% |
| Schroder Investment Management Ltd.as of 29 Feb 2024 | 875.08k | 1.18% |
| BlackRock Advisors (UK) Ltd.as of 04 Apr 2024 | 852.17k | 1.14% |
| Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 825.45k | 1.11% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
